Business
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
- FDA RMAT designation recognizes encouraging early data from Opus’ Phase 1/2 trial in patients with LCA5, an ultra-rare inherited retinal diseaseRESEARCH TRIANGLE PARK, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Regenerative Med
About this update from Opus Genetics, Inc.
[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/5903b8b33116d080342bdaf2c6a1b0bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xl5Pbyep4pXJ5VZR6DH1.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5903b8b33116d080342bdaf2c6a1b0bd","width":300,"height":129}},"lazy":false},{"type":"text","content":"- FDA RMAT designation recognizes encouraging early data from Opus’ Phase 1/2 trial in patients with LCA5, an ultra-rare inherited retinal disease","length":146,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OPGx-LCA5, its investigational gene therapy for the treatment of Leber Congenital Amaurosis (LCA) due to genetic variations in the LCA5 gene.","length":540,"tagName":"p"},{"type":"text","content":"The RMAT designation for OPGx-LCA5 is based on early clinical evidence from Opus’s ongoing Phase 1/2 open-label, dose-escalation trial, which is evaluating the safety and potential efficacy of OPGx-LCA5 in patients with severe vision loss due to confirmed mutations in the LCA5 gene. The FDA’s decision indicates recognition of the strength of this initial data and the unmet need in this patient population.","length":408,"tagName":"p"},{"type":"text","content":"“The FDA’s decision to grant RMAT designation to OPGx-LCA5 is a major milestone for the LCA5 patient community and a strong validation of our early clinical data,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “We’re encouraged by the potential of OPGx-LCA5 to meaningfully impact patients living with this ultra-rare and debilitating form of inherited blindness, and we look forward to continued collaboration with the FDA to accelerate its development.”","length":476,"tagName":"p"},{"type":"text","content":"In addition to the RMAT designation, Opus has ...